Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ESMO 2022 > Head and Neck Cancer > 5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC

5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC

Presented by
Dr Marcin Dzienis, Gold Coast University Hospital, Australia
Conference
ESMO 2022
Trial
Phase 4, KEYNOTE-B10
Doi
https://doi.org/10.55788/c84dafd0
    Pembrolizumab combined with 5-FU-free paclitaxel and carboplatin was effective and tolerable as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell cancer (R/M HNSCC) and may be an alternative for standard 5-FU containing regiment, preliminary results from the phase 4 KEYNOTE-B10 trial demonstrated.

    Standard-of-care treatment for patients with R/M HNSCC is pembrolizumab combined with 5-FU and platinum chemotherapy [1]. However, alternatives to 5-FU are needed based on their toxicities, patient inconvenience and complications [2]. The phase 4 KEYNOTE-B10 trial (NCT04489888) evaluated the efficacy and safety of pembrolizumab in combination with 5-FU-free carboplatin plus paclitaxel as first-line treatment for R/M HNSCC patients. Dr Marcin Dzienis (Gold Coast University Hospital, Australia) presented the first results of this ongoing study [3].

    The KEYNOTE-B10 trial enrolled all patients with previously untreated R/M HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx. Participants were treated with pembrolizumab (200 mg every 3 weeks) for ≤35 cycles, paclitaxel (100 mg/m2 every week on days 1 and 8; or 175 mg/m2 every 3 weeks on day 1) for 6 cycles, plus carboplatin (AUC 5 mg/mL/min every 3 weeks) for 6 cycles. The primary endpoint is the objective response rate (ORR). Results from the first 92 participants were presented.

    After a median follow-up of 8.2 months, 51 participants had discontinued treatment: 31 due to disease progression, and 10 due to adverse events. ORR was 42.7% (4.9% complete responders). ORR was irrespective of age, sex, HPV status, and PD-L1 expression. The median time-to-response was 1.5 months and the median duration of response was 5.5 months.

    Grade ≥3 treatment-related adverse events (AE) were observed in 70.7% of patients and serious treatment-related AEs in 17.4% of patients. The most common grade ≥3 treatment-related AEs were neutropenia, anaemia, and leukopenia.

    Based on these (preliminary) results, Dr Dzienis concluded: “Efficacy and safety results of this trial suggest that this 5-FU-free combination may be an alternative to the current standard-of-care.”

    1. Burtness B, et al. Lancet. 2019;394(10212):1915–1928.
    2. Guigay J, et al. Front Oncol. 2019;9:668.
    3. Dzienis M, et al. Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Abstract 651O, ESMO Congress 2022, 09–13 September, Paris, France.

    Copyright ©2022 Medicom Medical Publishers



    Posted on